相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
Yijin Li et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2021)
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P. A. Fasching et al.
ANNALS OF ONCOLOGY (2021)
Immunomodulation by targeted anticancer agents
Giulia Petroni et al.
CANCER CELL (2021)
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
J. Bryan Iorgulescu et al.
CLINICAL CANCER RESEARCH (2021)
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial
Xi Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot et al.
NATURE MEDICINE (2021)
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky et al.
JAMA ONCOLOGY (2021)
Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies
Musalula Sinkala et al.
COMMUNICATIONS BIOLOGY (2021)
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
A. Brufsky et al.
ANNALS OF ONCOLOGY (2021)
Mutant p53 suppresses innate immune signaling to promote tumorigenesis
Monisankar Ghosh et al.
CANCER CELL (2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
Germline genetic contribution to the immune landscape of cancer
Rosalyn W. Sayaman et al.
IMMUNITY (2021)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Targeted immunotherapy for HER2-low breast cancer with 17p loss
Yujing Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L. A. Emens et al.
ANNALS OF ONCOLOGY (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
P. Schmid et al.
ANNALS OF ONCOLOGY (2021)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
Jennifer Keating Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)-Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer
Hope S. Rugo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Systemic immunity in cancer
Kamir J. Hiam-Galvez et al.
NATURE REVIEWS CANCER (2021)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Katherine E. Hutchinson et al.
CLINICAL CANCER RESEARCH (2020)
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Bareche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Brian D. Lehmann et al.
CLINICAL CANCER RESEARCH (2020)
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)
Nadine Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The single-cell pathology landscape of breast cancer
Hartland W. Jackson et al.
NATURE (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Lillian M. Smyth et al.
CANCER DISCOVERY (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T. Karn et al.
ANNALS OF ONCOLOGY (2020)
Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.
Ayca Gucalp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
Priyanka Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).
Joyce O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).
Joohyuk Sohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
Eric P. Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
Johanna M. Schafer et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
Zheng Hu et al.
NATURE GENETICS (2020)
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer A Phase 3 Randomized Clinical Trial
Ke-Da Yu et al.
JAMA ONCOLOGY (2020)
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
Anne Fassl et al.
SCIENCE ADVANCES (2020)
Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
G. Bianchini et al.
ANNALS OF ONCOLOGY (2020)
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
D. W. Miles et al.
ANNALS OF ONCOLOGY (2020)
LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Z. Lwin et al.
ANNALS OF ONCOLOGY (2020)
NTRK1/2/3 fusions in secretory versus non-secretory breast cancers
T. Wilson et al.
ANNALS OF ONCOLOGY (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
Won Suk Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
ARe we there yet? Understanding androgen receptor signaling in breast cancer
Anna R. Michmerhuizen et al.
NPJ BREAST CANCER (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein et al.
NATURE CANCER (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
Primary and metastatic breast tumors cross-talk to influence immunotherapy responses
Amanda J. Oliver et al.
ONCOIMMUNOLOGY (2020)
Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
Yutian Zou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)
Sherene Loi et al.
CANCER RESEARCH (2020)
Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients
Marion van Mackelenbergh et al.
CANCER RESEARCH (2020)
Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Hyo (Heather) Han et al.
CANCER RESEARCH (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Luca Gianni et al.
CANCER RESEARCH (2020)
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
H. Raza Ali et al.
NATURE CANCER (2020)
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Mariya Rozenblit et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
C. Boddington et al.
LANCET (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Alessandro Prestipino et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
151OSingle agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial
K Yonemori et al.
ANNALS OF ONCOLOGY (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Targeting the PI3-kinase pathway in triple-negative breast cancer
J. Pascual et al.
ANNALS OF ONCOLOGY (2019)
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Johanna Wagner et al.
CELL (2019)
Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Steven Coats et al.
CLINICAL CANCER RESEARCH (2019)
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
Jake S. O'Donnell et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Ajjai Shivaram Alva et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
M. Oliveira et al.
ANNALS OF ONCOLOGY (2019)
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Max D. Wellenstein et al.
NATURE (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Johan Staaf et al.
NATURE MEDICINE (2019)
JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial
Li Bian et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Priyanka Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC) Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial
S. Loibl et al.
CANCER RESEARCH (2019)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
S Modi et al.
CANCER RESEARCH (2018)
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Elham Azizi et al.
CELL (2018)
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Max D. Wellenstein et al.
IMMUNITY (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
Daniel G. Stover et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Peter Savas et al.
NATURE MEDICINE (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Leeat Keren et al.
CELL (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
Marcelo Sobral-Leite et al.
ONCOIMMUNOLOGY (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
Jennifer R. Diamond et al.
BREAST CANCER RESEARCH (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UKTACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron et al.
LANCET ONCOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Michael A. Gordon et al.
MOLECULAR CANCER THERAPEUTICS (2017)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Paz Polak et al.
NATURE GENETICS (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
Rin Ogiya et al.
ONCOTARGET (2017)
Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC
Natasha K. Brockwell et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Jane Cullis et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer A Review
Miho Kono et al.
JAMA ONCOLOGY (2017)
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer The Randomized Clinical FinXX Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2017)
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
Thomas Karn et al.
JAMA ONCOLOGY (2017)
A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results.
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Uzma S. Asghar et al.
CLINICAL CANCER RESEARCH (2017)
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
Thomas M. Cardillo et al.
CLINICAL CANCER RESEARCH (2017)
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer
Anton Safonov et al.
CANCER RESEARCH (2017)
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
Wendie D. den Brok et al.
JCO PRECISION ONCOLOGY (2017)
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer
E. L. Korn et al.
ANNALS OF ONCOLOGY (2016)
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
Maurizio Callari et al.
CLINICAL CANCER RESEARCH (2016)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi et al.
CLINICAL CANCER RESEARCH (2016)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
New Strategies in Breast Cancer: Immunotherapy
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Joyce O'Shaughnessy et al.
CLINICAL CANCER RESEARCH (2015)
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial
Lucia y Del Mastro et al.
LANCET (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro)
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2014)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini et al.
LANCET ONCOLOGY (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET ONCOLOGY (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
S. Ohno et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer
Hong Lin et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Jeremy S. Logue et al.
GENES & DEVELOPMENT (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Balancing repair and tolerance of DNA damage caused by alkylating agents
Dragony Fu et al.
NATURE REVIEWS CANCER (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers
Giampaolo Bianchini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
Rafael Cubas et al.
MOLECULAR CANCER (2010)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer
Kathryn M. Taylor et al.
MOLECULAR MEDICINE (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial
M Venturini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer
S Yamashita et al.
NATURE (2004)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)